1-14 of 14
Lynn Navale
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Frederick L. Locke, Javier L. Munoz, Michael T. Tees, Lazaros J. Lekakis, Herbert A. Eradat, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz A. Malik, Geoffrey P. Shouse, Mehdi Hamadani, Olalekan O. Oluwole, Miguel-Angel Perales, David B. Miklos, Anh Nguyen, Amy Feng, Lynn Navale, Elaine Murray, Greg P. Kaufman, Kazuharu Kai, John B. Le Gall, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2095.
https://doi.org/10.1182/blood-2023-189196
Published: 2023
Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4620–4622.
https://doi.org/10.1182/blood-2022-158231
Published: 2022
Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4095.
https://doi.org/10.1182/blood-2019-125792
Published: 2019
Journal Articles

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, David B. Miklos, MD PhD, Eric D. Jacobsen, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 578.
https://doi.org/10.1182/blood.V130.Suppl_1.578.578
Published: 2017
Journal Articles

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric W. Van Den Neste, MD PhD, Umar Farooq, MD, Lynn Navale, MS, William Y. Go, MD PhD, Jeffrey S. Wiezorek, MD MS, Christian Gisselbrecht
Journal: Blood
Blood (2017) 130 (Supplement 1): 579.
https://doi.org/10.1182/blood.V130.Suppl_1.579.579
Published: 2017
Journal Articles

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Frederick L. Locke, MD, Jason R. Westin, MD, David B. Miklos, MD PhD, Alex F. Herrara, MD, Caron A. Jacobson, MD, Jennifer Lee, John M. Rossi, MS, Adrian Bot, MD PhD, Allen Xue, PhD, Lynn Navale, MS, Jeff S. Aycock, Jeffrey S. Wiezorek, MD MS, Zachary J. Roberts, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2826.
https://doi.org/10.1182/blood.V130.Suppl_1.2826.2826
Published: 2017
Journal Articles

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Marika Sherman, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD, David B. Miklos, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1547.
https://doi.org/10.1182/blood.V130.Suppl_1.1547.1547
Published: 2017
Journal Articles

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Clinical Trials & Observations
Michael Crump, Sattva S. Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K. Link, Annette Hay, James R. Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go, Christian Gisselbrecht
Journal: Blood
Blood (2017) 130 (16): 1800–1808.
https://doi.org/10.1182/blood-2017-03-769620
Published: 2017
Includes: Supplemental data
Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Bijal Shah, MD, Van Huynh, MD, Leonard S. Sender, MD, Daniel W. Lee, III, MD, Januario E. Castro, MD, William G. Wierda, MD PhD, Andrew C. Dietz, MD MSCR, Gary J. Schiller, MD, Marie José Kersten, MD PhD, Rupert Handgretinger, MD PhD, Patrick Brown, MD, Lia Gore, MD, Nicola Gökbuget, MD, Joseph Rosenthal, MD MS, Marianna Sabatino, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Shanna Stout, BS, Jeff S. Aycock, BA, Jeff Wiezorek, MD MS, Rajul Jain, MD, Alan S. Wayne, MD
Journal: Blood
Blood (2016) 128 (22): 2803.
https://doi.org/10.1182/blood.V128.22.2803.2803
Published: 2016
Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros Lekakis, MD, David Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John Timmerman, MD, Patrick J. Stiff, Jonathan Friedberg, MD, Ian Flinn, Andre Goy, MD, Mitchell Smith, Abhinav Deol, MD, Umar Farooq, MD, Peter McSweeney, MD, Javier Munoz, MD, Irit Avivi, MD, Januario E. Castro, MD, Jason R. Westin, MD MS, Julio C. Chavez, MD, Armin Ghobadi, MD, Krishna V. Komanduri, MD, Ronald Levy, MD, Eric D. Jacobsen, Patrick Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN, BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-6.
https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6
Published: 2016
Journal Articles

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Arianne Perez, PhD, Lynn Navale, MS, John M. Rossi, MS, Yueh-wei Shen, MS, Yizhou Jiang, PhD, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, Margo R. Roberts, PhD, David D. Chang, MD PhD, James N. Kochenderfer, MD, Adrian Bot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2042.
https://doi.org/10.1182/blood.V126.23.2042.2042
Published: 2015
Journal Articles

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Julio C. Chavez, MD, Chitra M. Hosing, MD, Armin Ghobadi, MD, Lihua E. Budde, MD PhD, Lynn Navale, MS, Jeff S. Aycock, BA, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3991.
https://doi.org/10.1182/blood.V126.23.3991.3991
Published: 2015
Journal Articles

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Yueh-wei Shen, MS, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, David D. Chang, MD PhD, James N. Kochenderfer, MD, Margo R. Roberts, PhD
Journal: Blood
Blood (2015) 126 (23): 4426.
https://doi.org/10.1182/blood.V126.23.4426.4426
Published: 2015
Journal Articles

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

John M. Rossi, MS, Sattva S. Neelapu, MD, William Y. Go, MD PhD, Yueh-wei Shen, MS, Marika Sherman, MS, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Lynn Navale, MS, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, Adrian Bot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2730.
https://doi.org/10.1182/blood.V126.23.2730.2730
Published: 2015